Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AIM ImmunoTech Inc. Director's Dealing 2023

Sep 29, 2023

35334_dirs_2023-09-29_f2b6ba79-8c54-4d4b-b957-fced46e6469e.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AIM ImmunoTech Inc. (AIM)
CIK: 0000946644
Period of Report: 2023-09-29

Reporting Person: Equels Thomas K (Director, CEO & President)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2023-09-29 Common Stock P 22676 $0.441 Acquired 606836 Direct